Guideline development requires the synthesis of evidence on several treatments of interest, typically by using network metaanalysis (NMA). Because treatment effects may be estimated imprecisely or be based on evidence lacking internal or external validity, guideline developers must assess the robustness of recommendations made on the basis of the NMA to potential limitations in the evidence. Such limitations arise because the observed estimates differ from the true effects of interest, for example, because of study biases, sampling variation, or issues of relevance. The widely used GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework aims to assess the quality of evidence supporting a recommendation by using a structured series of qualitative judgments. This article argues that GRADE approaches proposed for NMA are insufficient for the purposes of guideline development, because the influence of the evidence on the final recommendation is not taken into account. It outlines threshold analysis as an alternative approach, demonstrating the method with 2 examples of clinical guidelines from the National Institute for Health and Care Excellence (NICE) in the United Kingdom. Threshold analysis quantifies precisely how much the evidence could change (for any reason, such as potential biases, or simply sampling variation) before the recommendation changes, and what the revised recommendation would be. If it is judged that the evidence could not plausibly change by more than this amount, then the recommendation is considered robust; otherwise, it is sensitive to plausible changes in the evidence. In this manner, threshold analysis directly informs decision makers and guideline developers of the robustness of treatment recommendations.
Guideline development requires the synthesis of evidence on several treatments of interest, typically by using network metaanalysis (NMA). Because treatment effects may be estimated imprecisely or be based on evidence lacking internal or external validity, guideline developers must assess the robustness of recommendations made on the basis of the NMA to potential limitations in the evidence. Such limitations arise because the observed estimates differ from the true effects of interest, for example, because of study biases, sampling variation, or issues of relevance. The widely used GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework aims to assess the quality of evidence supporting a recommendation by using a structured series of qualitative judgments. This article argues that GRADE approaches proposed for NMA are insufficient for the purposes of guideline development, because the influence of the evidence on the final recommendation is not taken into account. It outlines threshold analysis as an alternative approach, demonstrating the method with 2 examples of clinical guidelines from the National Institute for Health and Care Excellence (NICE) in the United Kingdom. Threshold analysis quantifies precisely how much the evidence could change (for any reason, such as potential biases, or simply sampling variation) before the recommendation changes, and what the revised recommendation would be. If it is judged that the evidence could not plausibly change by more than this amount, then the recommendation is considered robust; otherwise, it is sensitive to plausible changes in the evidence. In this manner, threshold analysis directly informs decision makers and guideline developers of the robustness of treatment recommendations. H ealth technology assessments and guidelines require the synthesis of evidence on several treatments of interest from several studies. Typically, such analyses are performed by using network meta-analysis (NMA), which provides a consistent set of treatment effect estimates so that coherent recommendations may be made (1) (2) (3) . However, if the NMA estimates are imprecise, if studies included in the analysis have flaws in their conduct or reporting, or if concerns exist regarding relevance, the reliability of the NMA results may be in doubt. Therefore, analysts and decision makers need to assess the robustness of any conclusions based on the NMA to potential limitations in the included evidence.
The framework developed by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group, known as GRADE NMA (4, 5) , has been proposed to address this task.
A GRADE assessment rates the quality of evidence contributing to the treatment effect estimates for each pair of treatments as high, moderate, low, or very low across 5 domains-study limitations, imprecision, indirectness, inconsistency (heterogeneity), and publication biasand a qualitative summary judgment is formed (6) . The GRADE handbook (7) states 2 different aims for this quality assessment, depending on whether the intended users are systematic reviewers or guideline developers. For systematic reviewers, "the quality of evidence reflects the extent to which we are confident that an estimate of the effect is correct." For guideline developers, "the quality of evidence reflects the extent to which our confidence in an estimate of the effect is adequate to support a particular recommendation." GRADE NMA reaches a judgment for each treatment comparison by considering the individual GRADE judgments for the direct and indirect evidence between each pair of treatments. However, this approach does not provide guideline developers with an assessment of the credibility of recommendations based on the NMA. Instead, it delivers a set of independent assessments of the confidence in the estimates for individual pairwise comparisons. Moreover, GRADE NMA suggests replacing the NMA estimates with the direct or indirect estimates if they have a higher quality rating, leading to a set of final estimates that are not consistent with each other and therefore cannot be used for rational decision making (4). For example, it would be possible to obtain estimates in which intervention A is better than B, B is better than C, but C is better than A. Not only is it possible for GRADE NMA to reach a set of conclusions that are logically incoherent, it also fails to indicate how evidence quality might affect the final recommendation. As such, although GRADE NMA may achieve the prescribed aim for systematic reviewers, it is inadequate for guideline developers. The GRADE NMA ratings describe how likely each comparison estimate is to differ from the "truth," but the influence of evidence on the recommendation is not considered. For example, low-quality evidence that has negligible 
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influence on the treatment recommendation should be of little concern, but more influential evidence should be scrutinized carefully, and confidence in the robustness of the recommendation may be diminished. Recent advances in GRADE guidance acknowledge that the influence of evidence is important, suggesting that "there is no need to rate the indirect evidence when the [quality] of the direct evidence is high, and the contribution of the direct evidence to the network estimate is as least as great as that of the indirect evidence" (5). However, this reasoning is applied only to each pairwise comparison, and influence on the overall decision is not considered. Furthermore, GRADE NMA quickly becomes infeasible as the number of treatments in the network increases, because the number of loops of evidence that must be assessed grows very large (as in the example of social anxiety disorder discussed later).
An alternative, statistically rigorous extension of GRADE to NMA proposed by Salanti and colleagues (8) formally evaluates the influence of the direct evidence on each estimate and uses this to combine quality judgments from each piece of direct evidence into an overall quality assessment. This approach avoids the possibility of incoherent conclusions. Salanti GRADE has been implemented in the CINeMA (Confidence in Network Meta-analysis) Web application (9) , which automates the statistical operations and facilitates the required judgment steps, making it feasible even in large networks with many evidence loops, because the quality and contribution of indirect evidence are accounted for automatically. Salanti GRADE clearly meets the aim of quality assessment for systematic reviews and does so in a much more rigorous manner than GRADE NMA.
However, it still does not fully meet the aim of GRADE for guideline developers, because the quality assessments reflect the confidence in the NMA estimates, which does not necessarily translate into robustness of treatment recommendations: Evidence may be influential for an NMA result but may not actually change a decision (10) . In addition, it does not detail how potential bias would change a recommendation and therefore is less useful to decision makers and guideline developers than the approach described here, which directly assesses the robustness of the recommendations based on an NMA.
Network meta-analyses are based on data from studies of relative treatment effects. Both the study estimates and resulting NMA estimates may differ from the "true effects" of interest in the decision setting for 2 basic reasons: bias (systematic error) and sampling variation (random error). In the most general statistical sense, bias is any systematic departure from the truth. This may be a result of issues of internal validity (that is, study limitations) or external validity (affecting the generalizability of results into the decision setting). Sampling variation is captured by the CI, representing the uncertainty in the estimate, and typically is reduced as sample size increases. The issues addressed by the 5 GRADE domains all concern either bias (study limitations, inconsistency, indirectness, publication bias) or sampling variation (imprecision). From here on, we use the phrase change in the evidence to refer to any difference between an estimate and the true effect of interest, whether it is the result of bias or of sampling variation. Treatment recommendations may be made by using various decision criteria. The simplest is to choose the treatment with the "best" estimate on a particular outcome, such as the treatment with the highest mean reduction in pain, or on a composite outcome, such as a weighted average of outcomes (as in multicriteria decision making [11] ) or net monetary benefit (12) . Other formats include recommending the top few treatments with the highest mean estimates, treatments achieving a benefit above a certain cut point, the top treatments within a minimal clinically important difference, or a "do not do" recommendation against using the treatments with the worst outcomes. To determine the robustness of a treatment recommendation, we are concerned with whether there are plausible changes to the evidence that would translate into NMA estimates that lead to a different recommendation being reached.
Threshold analysis is a standard form of sensitivity analysis used in health economics. It answers the question: How much would the evidence have to change before the recommendation changes? (13) . In its basic form, we can simply rerun the NMA, iteratively changing the data until a new recommendation is reached (10) . These changes to the data may be made at 1 of 2 levels: either by changing an estimate from a single study (which we refer to as a study-level threshold analysis) or by changing the combined evidence on a contrast (relative effect) between 2 treatments (a contrast- Recently, a more sophisticated algebraic approach was proposed that does not require several reruns of the NMA (14); it requires only that the user supply the NMA estimates and the decision criteria. This method is computationally much faster and offers additional flexibility: We can consider potential changes to individual study estimates or to a set of estimates on a treatment comparison and examine the impact of specific potential biases. The analysis is not limited to greatest efficacy decisions: We can consider how changes in the evidence affect any treatment rankings-for example, to determine the robustness of a "do not do" decision for the worst treatment-and we can consider complex decision rules, such as those based on a minimal clinically important difference, and simple net benefit functions. An R (The R Foundation) package is available that makes the analysis quick and easy to conduct (https: //cran.r-project.org/package=nmathresh) (14, 15) .
THRESHOLD ANALYSIS IN PRACTICE
We illustrate threshold analysis in 2 practical examples taken from clinical guidelines produced by the National Institute for Health and Care Excellence (NICE). In the first, we show that the method may be used with large networks with complex modeling; in the second, we demonstrate an application with different formats for the recommendations. All R code is given in Supplement 1 (available at Annals.org), and a brief guide to performing threshold analysis with the R package nmathresh is given in Supplement 2 (available at Annals.org).
EXAMPLE: SOCIAL ANXIETY
Large networks with many treatments are common in guideline development. A NICE guideline for social anxiety disorder (CG159) included evidence on 41 treatments in 17 different classes from 100 studies, forming the evidence network in Figure 1 (16, 17) . On the basis of greatest efficacy, the base-case treatment recommendation is group cognitive behavioral therapy with phenelzine (treatment 41), which had the largest Figure 3 . The invariant interval for all psychological treatments against an inactive control, considered to be bias adjusted by the same amount on the SMD scale. Threshold Analysis in Guideline Development RESEARCH AND REPORTING METHODS estimated reduction in symptoms of social anxiety (most negative standardized mean difference [SMD]), Ϫ1.68 (95% CrI, Ϫ2.10 to Ϫ1.27), compared with placebo. GRADE NMA simply is not practicable in this scenario: 820 possible pairwise comparisons exist, 84 of which are directly informed by studies, and the number of indirect evidence loops is very large. However, we can easily perform a threshold analysis to assess the robustness of the recommendation; the results are shown in Figure 2 . Each row of the figure corresponds to a comparison between 2 treatments for which direct study evidence was available, sorted to show comparisons with smallest thresholds first. We visualize the positive and negative thresholds for each comparison by creating invariant intervals, plotted as shaded lines. These are formed by adding the positive and negative thresholds (listed in Appendix Table 1 , available at Annals.org) to the point estimate, to show how much the combined evidence on each comparison would have to change before a new treatment decision is reached. Changes to the evidence within the invariant interval do not alter the treatment recommendation. If evidence were to change beyond the thresholds at either end of the invariant interval, then new treatment decisions would be reached; these are presented in Figure 2 (with treatment codes) at the corresponding side of the invariant interval. Some comparisons have no threshold in one direction (indicated by NT), so no amount of change to the evidence in this direction would alter the recommendation. The smallest threshold (Appendix Table 1 ) is a positive change of 0.46 in the estimate of Ϫ0.88 SMD for the 41-versus-31 comparison (that is, the upper limit of the invariant interval is Ϫ0.88 + 0.46 = Ϫ0.42), at which point cognitive therapy (treatment 36) would be recommended. At the negative side of the invariant interval for the 41-versus-31 comparison, no threshold exists-no amount of change in the negative direction to the evidence on this comparison (that is, becoming even more favorable to treatment 41) could ever result in a new recommendation. In total, only 5 comparisons have thresholds smaller than 0.8 SMD-a value considered large (18)-and for each of these, the new treatment recommendation would be cognitive therapy, which was ranked second in the original NMA. For the remaining 79 comparisons, we judge that the magnitude of change required to alter the treatment decision is unrealistically large; therefore, the treatment recommendation is robust to plausible changes to these comparisons. As this example shows, with such large networks, typically only a few contrasts are decision sensitive and require further scrutiny, whereas GRADE NMA may be infeasible.
We also use threshold analysis to examine the potential impact of more complex biases, exploring concerns in sets of treatment comparisons or studies. For example, it is plausible that the effects of psychological interventions are overestimated compared with inactive control, perhaps because of difficulties in blinding. Threshold analysis (Figure 3 ) reveals that adjusting for such bias (if present) would change the treatment recommendation only if the effects were overestimated by at least 1.54 SMD. This threshold is implausibly large and would require most psychological treatments to in fact be harmful. The recommendation therefore is considered robust to plausible overestimation of the psychological treatment effects.
EXAMPLE: HEADACHES
Threshold analysis may also be applied to more complex decision rules. A NICE clinical guideline (CG150) examined 8 prophylactic treatment regimens for chronic or episodic migraine (19) ; an NMA was performed on a treatment network formed of 11 studies comparing the 8 treatments (Figure 4) . A minimal clinically important difference of 0.5 headache days per month was defined, with which we form a decision rule: Recommend any treatment that shows a reduction of 0.5 days or more compared with placebo and is within 0.5 days of the most effective treatment. On the basis of this decision rule, propranolol, with an expected change in headache days of Ϫ1.19 (CrI, Ϫ2.20 to Ϫ0.20); topiramate, with a change of -1.04 (CrI, Ϫ1.52 to Ϫ0.58); and amitriptyline, with a change of Ϫ1.14 (CrI, Ϫ2.45 to 0.16), were recommended.
Applying threshold analysis to the body of evidence on each comparison ( Figure 5) , we see that the CrIs for the evidence on each comparison extend beyond the limits of the invariant intervals; therefore, the recommendation is sensitive to the level of uncertainty in the data (which also is reflected in the CrIs for the treatment effects). The smallest threshold (see also Appendix Table 2 , available at Annals.org) is Ϫ0.09 days (just over 2 hours per month) for the comparison of propranolol-nadolol versus placebo (8 vs. 1), at which point propranolol-nadolol joins the recommended set of treatments. Because propranolol-nadolol was very close to within 0.5 days of propranolol (the most effective treatment) in the original analysis, this result is not surprising. We might expect bias to exaggerate the effect of treatment compared with placebo, but the small thresholds for comparisons of treatments 2, 4, 5, and 8 versus placebo are for changes in 
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Threshold Analysis in Guideline Development the opposite direction. Any bias in the evidence on these comparisons therefore is unlikely to change the decision; the decision is still sensitive to the level of uncertainty in the evidence, however. Of note, the GRADE assessments in Figure 5 do not show any relationship to the magnitude of the thresholds. As observed previously (10), evidence quality is unrelated to the influence of evidence on the results of the NMA. The combined body of evidence on a contrast often involves more than one study, and these studies are likely to have different characteristics and risk-of-bias assessments and to have a greater or lesser influence on the treatment recommendation. Threshold analysis may also be applied to the individual study estimates to determine sensitivity at the study level. Details of the studies included in the original NMA, including references, are found in the addendum to NICE CG150 (19) . Figure 6 gives the results of a study-level threshold analysis, showing that the recommendation is sensitive to the level of imprecision in 6 of 11 studies. The thresholds for the remaining 5 studies are larger, and a judgment is required on whether changes of plausible magnitude and direction could surpass these thresholds (see also Appendix Table 3 , available at Annals.org). Thresholds that might plausibly result in a treatment dropping out of the recommended set are found for only 2 studies (Diener 2004 and Dodick 2009), so these studies may be prioritized for further scrutiny. Risk-of-bias assessments ( Figure 6 ) are low or unknown in all domains for Dodick 2009, but a high risk of attrition bias exists for Diener 2004 that should be investigated further. For 6 studies, there are no thresholds in one direction, so no amount of change in this direction could alter the recommendation.
The results of the threshold analysis should lead to further scrutiny of the study evidence to which the recommendation is sensitive and may placate any concerns raised about studies to which the treatment recommendation is not as sensitive.
DISCUSSION
Threshold analysis is a powerful tool for analysts and decision makers to examine the sensitivity of decisions to potential changes in the evidence. Conducting a threshold analysis requires a basic ability to prepare data in R and to call the R package. Interpretation of the results does not require technical knowledge and is best performed by clinical or content experts in a guideline development group with some statistical guidance. Such frameworks as GRADE cannot by themselves evaluate the robustness of a treatment recommendation, because the influence of each piece of evidence on the recommendation is not taken into account. The thresholds and invariant intervals produced by a threshold analysis directly indicate how sensitive a decision is to each piece of evidence, which should then be combined with judgments of the plausible magnitude and direction of bias, informed by assessments such as the Cochrane Risk of Bias Tool (20) . The meta-epidemiologic literature on the empirical evidence for bias is likely to be helpful in this regard, once potential biases in the evidence have been identified (21, 22) . Considering the effects of several potential changes simultaneously is also possible (14) . The resulting multidimensional thresholds are straightforward to compute, but visualization is challenging; some suggestions are discussed in an earlier publication (14) .
Recently, the GRADE Evidence to Decision (EtD) framework (23, 24) was proposed to support the development of health care guidelines and policy. One of the criteria presented in EtD tables is the "certainty" of the evidence. The EtD framework proposes using GRADE to assess certainty. However, threshold analysis is arguably more relevant to the assessment of evidence certainty in the EtD context, because it directly evaluates the sensitivity of treatment recommendations to changes in the evidence.
GRADE NMA, Salanti GRADE, and threshold analysis all require subjective judgments in their application 64 to 0.45)  (−1.13 to 1.32)  (−1.11 to 0.82)   2, 3, 6, 7  3, 4, 6, 7  3, 5, 6 The base-case optimal set of treatments is 3, 6, 7 (amitriptyline, topiramate, propranolol). At either side of the invariant interval is the new set of optimal treatments if threshold exceeded in this direction. CrI = credible interval; GRADE = Grading of Recommendations Assessment, Development and Evaluation; NT = no threshold (no amount of change in this direction would change the recommendation).
Threshold Analysis in Guideline Development RESEARCH AND REPORTING METHODS or interpretation. However, the level of subjectivity differs among the 3 approaches. GRADE NMA and Salanti GRADE both make structured but subjective judgments of the quality of each piece of evidence. GRADE NMA then combines these judgments subjectively to reach an overall judgment, whereas Salanti GRADE uses an objective statistical rationale to reach an overall judgment. Further subjectivity in interpreting the GRADE judgment is one of the challenges raised in a previous commentary (25) , along with reproducibility and predictive validity. In comparison, threshold analysis is objective in deriving thresholds and determining the respective changes in treatment recommendation, both of which follow from the mathematical structure of the NMA. Interpretation of these thresholds then requires subjective judgments of the plausible magnitude and direction of changes in the evidence, which may be informed by risk-of-bias assessments and the metaepidemiologic literature on bias (21, 22) . This is not a trivial task and is a potential limitation; however, the authors piloted the method in a live guideline development scenario and found the required judgments to be feasible (26).
For simplicity, the 2 examples presented here focus on decisions based on efficacy; in reality, both guidelines ultimately made treatment recommendations on the basis of cost-effectiveness (along with other considerations, such as licensing arrangements in the United Kingdom), as is usual in guidelines produced by NICE. Threshold analysis is applicable within a cost-effectiveness framework, and algebraic solutions may be found for simple economic models (14) ; however, this is not possible in general. Alternative approaches to applying threshold analysis for costeffectiveness decisions therefore are an area for further research. For decision rules based on statistical "significance" rather than on expected treatment effects, numerical methods are needed to determine the thresholds. The current algebraic approach determines the influence of the evidence only on the point estimates and not on the uncertainty.
Threshold analysis is just one of several sensitivity analyses that may be used to assess the robustness of an NMA and the resulting recommendations. One common approach is to remove from the analysis all studies at high risk of bias. However, this may lead to issues 
The base-case optimal set of treatments is 3, 6, 7 (amitriptyline, topiramate, propranolol). Green type indicates studies with thresholds within the 95% CI. References for the included studies are found in reference 19. The risk-of-bias table is displayed to the right of the plot. At either side of the invariant interval is the new set of optimal treatments if threshold exceeded in this direction. Risk of bias is judged as low (L), high (H), or unknown (U) in 6 domains: selection (Sel), performance (Perf), detection (Det), attrition (Att), reporting (Rep), and other (Oth). NT = no threshold (no amount of change in this direction would change the recommendation).
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Threshold Analysis in Guideline Development such as disconnected networks or removal of treatments of interest. Threshold analysis allows a more informative assessment of the potential impact of high-risk studies while avoiding such problems. Meta-regression offers the possibility of adjusting for biases that are suspected to be present but typically requires external evidence on bias (27) (28) (29) (30) . Threshold analysis is always possible, regardless of the number of studies in the analysis, because no bias estimation is performed.
Although we have demonstrated the use of threshold analysis for NMA, the ideas and processes apply equally to pairwise meta-analysis as a special case. We suggest that threshold analysis be integrated into the guideline development process as follows: Before analysis, the included studies should be assessed for risk of bias (20, 31) and a decision rule formulated, as is the current best practice. Once the (network) meta-analysis has been performed, threshold analysis should be used to determine the sensitivity to the evidence on individual comparisons (for NMA) and to each study. Further threshold analyses may then be used to address more specific concerns, such as biases in sets of treatment comparisons or studies. If sensitivities are identified, the plausible magnitude and direction of potential changes in the evidence should be investigated. The impact (if any) of plausible changes in the evidence is then easily determined, and decision makers can incorporate knowledge of robustness or sensitivity into their recommendations. 
